Therefore, an implication of the recently uncovered regulatory and metabolic pathways controlled by IL4i1 and IDO1 is that inhibition of one enzyme in cancer therapy may be insufficient to block ferroptosis suppression, AhR activation, tryptophan depletion or downstream metabolic supply via 1-carbon and NAD metabolism. The gene discussed is IL4I1; the disease is cancer.